01dragonslayer
Iron Killer
Mad Referrer
Jacked Immortal
EG Auction Sniper
VIP Member
Shout Master
Mutated
Fully Loaded
- EG Cash
- 1,113,693
TB-500 also known as Thymosin Beta 4 is a naturally occurring peptide. It is found in high concentrations in blood platelets, wound fluid and other tissues in the body. TB-500 is not a growth factor; rather, it is a major actin regulating peptide. TB-500 (Thymosin Beta 4) has been found to play an important role in protection, regeneration and remodeling of injured or damaged tissues. The gene for TB-500 (Thymosin Beta 4) has also been found to be one of the first to be upregulated after a wound occurs.
Numerous preclinical studies have indicated multiple biologic activities for TB-500 (Thymosin Beta 4) Tβ4, specific to different tissues types.
Myocardial Development of TB-500 (Thymosin Beta 4 Peptide)
Recent clinical studies performed by REGENERX BIOPHARMACEUTICALS were presented at the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy. They presented the results of the biological properties that support TB-500 (Thymosin Beta 4) Tβ4’s near term and long term clinical applications. It was noted that special emphasis is being placed on the development of TB-500 for the systemic treatment of patients with ST-elevation myocardial infarction (STEMI) in combination with percutaneous coronary intervention, the current standard of care in most western countries for this common type of heart attack. The goal with TB-500 (Thymosin Beta 4) peptide is to prevent or repair continued damage to cardiac tissue post-heart attack, when such tissue around the damaged site remains at risk.
The most current results on the Phase I safety study with TB-500 entitled, “A Randomized, Double-blind, Placebo-controlled, Dose-response Phase I Study of the Safety and Tolerability of the Intravenous Administration of TB-500 (Thymosin Beta 4) peptide and its Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers.” The study concluded with “There were no dose limiting or serious adverse events throughout the dosing period. Synthetic TB-500 (Thymosin Beta 4) Tβ4 administered intravenously up to 1260 mg, and for up to 14 days, appears to be well tolerated with low incidence of adverse events and no evidence of serious adverse events.” According to Dr. Dennis Ruff, vice president and medical director of ICON.
Numerous preclinical studies have indicated multiple biologic activities for TB-500 (Thymosin Beta 4) Tβ4, specific to different tissues types.
Myocardial Development of TB-500 (Thymosin Beta 4 Peptide)
Recent clinical studies performed by REGENERX BIOPHARMACEUTICALS were presented at the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy. They presented the results of the biological properties that support TB-500 (Thymosin Beta 4) Tβ4’s near term and long term clinical applications. It was noted that special emphasis is being placed on the development of TB-500 for the systemic treatment of patients with ST-elevation myocardial infarction (STEMI) in combination with percutaneous coronary intervention, the current standard of care in most western countries for this common type of heart attack. The goal with TB-500 (Thymosin Beta 4) peptide is to prevent or repair continued damage to cardiac tissue post-heart attack, when such tissue around the damaged site remains at risk.
The most current results on the Phase I safety study with TB-500 entitled, “A Randomized, Double-blind, Placebo-controlled, Dose-response Phase I Study of the Safety and Tolerability of the Intravenous Administration of TB-500 (Thymosin Beta 4) peptide and its Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers.” The study concluded with “There were no dose limiting or serious adverse events throughout the dosing period. Synthetic TB-500 (Thymosin Beta 4) Tβ4 administered intravenously up to 1260 mg, and for up to 14 days, appears to be well tolerated with low incidence of adverse events and no evidence of serious adverse events.” According to Dr. Dennis Ruff, vice president and medical director of ICON.
